Table of Contents
✨ Onyx Summary
Sinaptica Therapeutics received funding from the Centre for Aging + Brain Health Innovation (CABHI), in partnership with Baycrest, to support development and validation of its personalized, non-invasive neuromodulation system for Alzheimer’s disease.
The funding deepens Sinaptica’s collaboration with Baycrest and supports advancement toward clinical readiness and future patient access in Canada as the company prepares for a pivotal randomized controlled trial.
Cambridge, MA – December 11, 2025 – Sinaptica Therapeutics, Inc., a clinical-stage company leading the development of a new class of personalized neuromodulation therapeutics to treat Alzheimer’s and other primary neurodegenerative diseases, has received funding from The Centre for Aging + Brain Health Innovation (CABHI), in partnership with Baycrest, one of North America’s leading academic health sciences centers focused on brain health and aging.
The funding will support continued development and validation of Sinaptica’s novel neuromodulation system and deepen collaboration with Baycrest, a critical partner to accelerate access to neuromodulation therapy for patients and clinicians in Canada. Baycrest treats more than 10,000 patients annually across a broad range of neurological and cognitive disorders on its 23-acre campus.
“This collaboration represents an important opportunity for Sinaptica,” said Ken Mariash, CEO of Sinaptica Therapeutics. “Baycrest is internationally recognized for its scientific leadership, clinical expertise, and scale in brain health. Working together allows us to accelerate innovation while laying the foundation for future clinical research and, ultimately, patient access.”
The funding is provided through CABHI’s Fuel program to accelerate cutting-edge aging and brain health solutions., which supports early- to mid-stage researchers and companies in achieving milestones related to research and development, product testing, and validation. Beyond financial support, innovators benefit from a tailored suite of CABHI’s Acceleration Services, strategically crafted to streamline their innovation journey and pathway to market. Sinaptica received the funding through its Therapeutics Canada, Ltd. subsidiary.
About the Centre for Aging + Brain Health Innovation
The Centre for Aging + Brain Health Innovation (CABHI), powered by Baycrest, was established in 2015 to support researchers, clinicians, and innovators, as they develop and adopt transformative innovations that improve the lives of older persons, including those impacted by dementia. CABHI is a unique collaboration of healthcare, science, industry, not-for-profit, and government partners. Through its funding programs and tailored acceleration services, including access to diverse end-user groups, CABHI advances transformative aging and brain health innovations across Canada and the world. For more information, visit: www.cabhi.com.
About Baycrest
At Baycrest, our vision is a world where every older person lives with purpose, fulfilment and dignity. Baycrest is a global leader in aging and brain health innovation, with over 105 years of expertise in seniors’ care and cutting-edge research. Baycrest has been Designated with Exemplary Status by Accreditation Canada, and drives industry-leading care and safety outcomes. As the home of the Centre for Aging + Brain Health Innovation (CABHI) powered by Baycrest, the Baycrest Academy for Research and Education (BARE) and the Canadian Consortium on Neurodegeneration in Aging, Baycrest is at the forefront of dementia research. Affiliated with the University of Toronto, Baycrest’s training programs shape the future of care globally, while Baycrest Global Solutions extends its expertise to senior living and healthcare internationally. For more information, visit: baycrest.org.
About the SinaptiStim® System
The SinaptiStim® System is an investigational new approach to treating Alzheimer’s disease using non-invasive personalized precision neuromodulation. Calibrated to each individual’s brain, the therapy is delivered in weekly 20-minute sessions in a recliner. The SinaptiStim system delivers safe, painless, customized neurostimulation technology targeting the Default Mode Network (DMN), an important brain network associated with episodic memory, introspection, and other cognitive functions. The technology was granted Breakthrough Device Designation by the FDA in 2022.
The company is preparing for a pivotal randomized controlled clinical trial in mild-to-moderate Alzheimer’s. In this trial, the treatment will be calibrated quarterly using TMS and EEG concurrently in combination with MRI-guided neuronavigation, which enables the SinaptiStim System to achieve customized precise repeatable targeting and safe-yet-effective dosage for each patient, tracking progress and adjusting over time to achieve the best possible individualized outcomes with its nDMN therapy. The pivotal trial will also be designed to determine the effects of SinaptiStim® System on several biomarkers measuring beta amyloid, phosphorylated tau, neuroinflammation, and synaptic dysfunction.
About Sinaptica Therapeutics
Sinaptica Therapeutics is a clinical-stage neuromodulation therapeutics company leading the development of a new class of novel personalized therapeutics to revolutionize the treatment of Alzheimer’s and other primary neurodegenerative diseases. The company utilizes a patented non-invasive approach to treating Alzheimer’s via precision neurostimulation of a key brain network involved in memory, the Default Mode Network. Sinaptica’s scientific co-founders pioneered research on this novel approach which a growing body of evidence indicates can slow disease progression. Sinaptica’s mission is to bring a safe, effective, and non-invasive neuromodulation therapy to Alzheimer’s patients that can help to significantly slow the progression of cognitive, functional, and behavioral decline. Learn more at sinapticatx.com and follow us on LinkedIn and Twitter @SinapticaTX.
The SinaptiStim™ System is for investigational use only. It has not been approved by the U.S. Food and Drug Administration and is not available for commercial sale in any geography.
Media contact:
Kathryn Morris, BrightPoint
kathryn@brightpointny.com
914-204-6412
